Johnson G F, Hunt G E, Caterson I
Department of Psychiatry, University of Sydney, Australia.
J Affect Disord. 1988 Jul-Aug;15(1):93-100. doi: 10.1016/0165-0327(88)90014-6.
Plasma dexamethasone concentrations following oral dexamethasone administration were examined in 78 patients with major depression prior to and during treatment. The test-retest stability of plasma dexamethasone levels within patients was satisfactory with an overall significant positive correlation between tests for each patient. However, significant variability was noted in individual patients. Change in pre-DST cortisol and plasma dexamethasone levels were the two variables, in that order of importance, contributing to change in DST status. In studies examining the clinical utility of serial dexamethasone suppression tests as a guide to recovery from depression, the effect of variability in plasma dexamethasone concentrations should be taken into account.
在78例重度抑郁症患者治疗前及治疗期间，对口服地塞米松后的血浆地塞米松浓度进行了检测。患者体内血浆地塞米松水平的重测稳定性良好，每位患者的两次检测之间总体呈显著正相关。然而，个别患者存在显著差异。地塞米松抑制试验前的皮质醇和血浆地塞米松水平变化是导致地塞米松抑制试验结果变化的两个变量，按重要性排序。在研究连续地塞米松抑制试验作为抑郁症康复指导的临床效用时，应考虑血浆地塞米松浓度变异性的影响。
